This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Renal Injury Prompts Label Changes for Osteoporosis Drug
Reclast Linked to Acute Renal Failure, Deaths in At-risk Patients
By News Staff
The drug label for the zoledronic acid product marketed as Reclast has been updated after the osteoporosis medication was linked to 16 deaths from acute renal failure, the FDA said in a Sept. 1 safety announcement. The agency also reported nine cases of renal injury requiring dialysis after Reclast infusions.
The FDA said rare cases of renal failure have been reported in patients taking Reclast who had a history of or risk factors for renal impairment, including concomitant use of nephrotoxic or diuretic medications or severe dehydration occurring before or after Reclast was given.
The risk of developing renal failure in patients with underlying renal impairment also increases with age, the FDA said.
The agency said no labeling changes are being required for the zoledronic acid product marketed as Zometa, which is approved for treatment of cancer-related indications and which already provides dose-reduction information for patients with renal impairment and addresses renal toxicity in the warnings and precautions section of its label.
Reclast is given as an intravenous infusion in a single dose once every one to two years to treat or prevent osteoporosis in women after menopause, increase bone mass in men with osteoporosis, treat or prevent osteoporosis in men or women who take corticosteroid medications for at least one year, or treat men and women who have Paget's disease of bone.
The FDA issued the following information for physicians:
The risk of developing renal failure in patients with underlying renal impairment also increases with age, the FDA said.
The agency said no labeling changes are being required for the zoledronic acid product marketed as Zometa, which is approved for treatment of cancer-related indications and which already provides dose-reduction information for patients with renal impairment and addresses renal toxicity in the warnings and precautions section of its label.
Reclast is given as an intravenous infusion in a single dose once every one to two years to treat or prevent osteoporosis in women after menopause, increase bone mass in men with osteoporosis, treat or prevent osteoporosis in men or women who take corticosteroid medications for at least one year, or treat men and women who have Paget's disease of bone.
The FDA issued the following information for physicians:
- Reclast is contraindicated in patients with creatinine clearance less than 35 mL/minute or in patients with evidence of acute renal impairment.
- Calculate creatinine clearance before each dose of Reclast. Interim monitoring of creatinine clearance should be performed after Reclast dosing in at-risk patients. Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula.
- Screen patients before each infusion of Reclast to identify those with underlying acute or chronic renal impairment, advanced age or dehydration. Patients with underlying renal impairment appear to be at highest risk for kidney failure, and the drug should be used with caution in this population.
- The risk of acute renal failure may increase with underlying renal disease and dehydration secondary to fever, sepsis, gastrointestinal losses, diuretic therapy or other causes. The risk of developing renal failure in patients with renal impairment also increases with age.
- Report adverse events associated with Reclast to the FDA's MedWatch program.
Share this on AAFP Connection
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Search AAFP News Now
Health of the Public
Remain Vigiliant for Novel Coronavirus, Says CDC
DTaP Remains in Short Supply This Summer
Though Waning, H7N9 Still Poses Pandemic Potential
AUA Says No to Routine PSA Screening
AAFP Criticizes Appeal of Plan B One-Step Ruling
AAFP to Hospitals: Stop Early Elective Deliveries
AAFP, USPSTF Differ Somewhat on HIV Screening Guidance
Zoledronic Acid Confers Both Pros, Cons
ACP Issues Guidance on PSA Screening
Abbott Recalls FreeStyle InsuLinx Blood Glucose Meter
Discuss Drug Options With Women at Risk for Breast Cancer
Shingles Vaccine Effective, But Uptake Is Low
Evidence Lacking to Make Oral Cancer Screening Recommendation
Two External Guidelines Get Qualified AAFP Endorsement
USPSTF Recommends BRCA Testing for High-risk Women
Primary Care, Public Health Look for Ways to Integrate
Malfunction Prompts Glucose Meter Recall
Evidence Lacking on PAD Screening, Says USPSTF
Azithromycin Poses Arrhythmia Risk, Says FDA
Vets With PTSD Often Prescribed Inappropriate Meds
AIM-HI Offers Grants to Combat Childhood Obesity
USPSTF Says No to Low-dose Vitamin D, Calcium to Prevent Fractures
PCV13, HibMenCY Vaccine Changes Approved by ACIP
AAFP, Other Groups Release More Choosing Wisely Lists
National Office Champions Tobacco Cessation Project Successful
USPSTF Issues Draft Statement on Glaucoma Screening
Study Examines Overuse, Inappropriate Use of Health Services
Apply to Become an AAFP Vaccine Science Fellow
Study Looks to Reduce PSA Screening Risks
AAP Issues New Clinical Guidance on Type 2 Diabetes
CDC: Adult Vaccination Rates Still Too Low
Pertussis Outbreaks Declining, but Immunization Still Key
2013 Immunization Schedules Include Several Changes
FDA Warns of Liver Injury Risk With Samsca Use
FDA Approves First Recombinant Trivalent Influenza Vaccine
AAFP, USPSTF: Screen Women of Childbearing Age for Partner Violence
Breast Cancer Screening in Older Women Costly, Likely Ineffective
CDC Gives Flu Update, Urges Continued Vaccination
Aerobic Exercise Beats Resistance Training for Weight Control